# EDGAR Filing Document

**Accession Number:** 0001333141
**File Stem:** 0001104659-26-002607
**Filing Date:** 2026-1
**Character Count:** 8148
**Document Hash:** 593b28dfdde623e14c93b9f6c770b9a2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-002607.hdr.sgml**: 20260112

**ACCESSION NUMBER**: 0001104659-26-002607

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 4

**CONFORMED PERIOD OF REPORT**: 20260112

**FILED AS OF DATE**: 20260112

**DATE AS OF CHANGE**: 20260112

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Fresenius Medical Care AG
- **CENTRAL INDEX KEY:** 0001333141
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-32749
- **FILM NUMBER:** 26524523

**BUSINESS ADDRESS:**
- **STREET 1:** ELSE-KROENER STRASSE 1
- **CITY:** BAD HOMBURG
- **STATE:** 2M
- **ZIP:** 61352
- **BUSINESS PHONE:** 011-49-6172-6090

**MAIL ADDRESS:**
- **STREET 1:** ELSE-KROENER STRASSE 1
- **CITY:** BAD HOMBURG
- **STATE:** 2M
- **ZIP:** 61352

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Fresenius Medical Care AG & Co. KGaA
- **DATE OF NAME CHANGE:** 20050714

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

Pursuant to Rule 13a-16 or 15d-16 of the

Securities Exchange Act of 1934

For the month of January 2026

Commission file number: 001-32749

**FRESENIUS MEDICAL CARE AG**

(Translation of registrant's name into English)

Else-Kröner Strasse 1

61346 Bad Homburg

Germany

*(Address of principal executive offices)*

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ⌧ Form 40-F ◻

**EXHIBITS**

The following exhibits are being furnished with this Report:

---

| | |
|:---|:---|
| [Exhibit 99.1](tm262757d1_ex99-1.htm) | [Convenience translation of information disclosed on January 9, 2026 according to Article 17 Market Abuse Regulation (MAR) of the Regulation (EU) No 596/2014.](tm262757d1_ex99-1.htm) |
| [Exhibit 99.2](tm262757d1_ex99-2.htm) | [Press Release issued on January 9, 2026.](tm262757d1_ex99-2.htm) |

---

The exhibits furnished with this report do not, individually or in the aggregate, constitute an offer to purchase or a solicitation of any offer to sell any securities.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

DATE: January 12, 2026

---

| | |
|:---|:---|
| Fresenius Medical Care AG | Fresenius Medical Care AG |
| By: | /s/ Helen Giza |
| Name: | Helen Giza |
| Title: | Chief Executive Officer and Chair of the Management Board |

---

---

| | |
|:---|:---|
| By: | /s/ Martin Fischer |
| Name: | Martin Fischer |
| Title: | Chief Financial Officer and member of the Management Board |

---

## Exhibit 99.1

**Exhibit 99.1**

**Fresenius Medical Care AG is continuing its share buyback program in an accelerated manner**

Bad Homburg, January 9, 2026 – Fresenius Medical Care AG ("Company") has decided to continue the share buyback program announced in an ad-hoc release on June 17, 2025, by repurchasing a second tranche. The share buyback program has a total volume of EUR 1 billion (excluding ancillary costs).

The first tranche of the Company's share buyback program was completed ahead of schedule on December 29, 2025.

With the second tranche it is intended to repurchase own shares for a total amount of around EUR 415 million from January 12, 2026, to May 8, 2026 (inclusive). The share buyback program is therefore expected to be completed significantly earlier. The shares shall be acquired on the stock exchange and are to be predominantly redeemed and, to a significantly lesser extent, may be used for allocations under incentive-based compensation plans.

The share buyback program is based on the authorization to purchase and use treasury shares granted by the Company's Annual General Meeting on May 20, 2021.

Contact:

Dr. Dominik K. Heger

Head of Investor Relations, Market & Competition, Sustainability

Executive Vice President

<u>Dominik.Heger@FreseniusMedicalCare.com</u>

+49 6172 2685822

## Exhibit 99.2

**Exhibit 99.2**

![](tm262757d1_ex99-2img01.jpg)

---

| | |
|:---|:---|
| Press Release | **Media contact**<br> Christine Peters<br> T +49 160 60 66 770<br> christine.peters@freseniusmedicalcare.com<br>**Contact for analysts and investors**<br> Dr. Dominik Heger<br> T +49 6172 609 2601<br> dominik.heger@freseniusmedicalcare.com<br>www.freseniusmedicalcare.com |

---

**Fresenius Medical Care accelerates the second tranche of its EUR 1 billion share buyback program with around EUR 415 million repurchase planned** 

&nbsp;&nbsp;&nbsp;&nbsp;· The second tranche of the share buyback is expected to be executed by May
8, 2026

&nbsp;&nbsp;&nbsp;&nbsp;· The share buyback program with a total volume of EUR 1 billion is expected
to be completed in less than a year, significantly earlier than originally planned

**Bad Homburg (January 9, 2026)** – Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal disease, will accelerate its share buyback program and start the repurchase of the second tranche. The program – presented during the company's Capital Markets Day on June 17, 2025 – has a total volume of EUR 1 billion. Under the second tranche, the company plans to repurchase its own shares for a total amount of around EUR 415 million from January 12 to May 8, 2026.

The first tranche of the company's share buyback program was completed ahead of schedule on December 29, 2025. The share buyback program, which is part of the FME capital allocation framework within the 'FME Reignite' strategy, is expected to be completed significantly earlier than originally planned, in less than a year.

Helen Giza, CEO and Chair of the Management Board, said, "The successful acceleration of our EUR 1 billion share buyback program is supported by our strong financial performance and consistent execution against our 'FME Reignite' strategy, with a focus on value creation and delivering returns to our shareholders."

"Our strong cash-flow generation on the back of continued business momentum enables an acceleration of our share buyback program, demonstrating the effectiveness of our new capital allocation framework," said Martin Fischer, CFO of Fresenius Medical Care.

Page 1/ 2

FME will provide regular updates on the progress of the share buyback program at <u>https://freseniusmedicalcare.com/en/investors/shares/share-buy-back/</u>

About Fresenius Medical Care:

Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 4.2 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,628 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approximately. 294,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines and dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).

For more information visit the Company's website at <u>www.freseniusmedicalcare.com</u>.

Disclaimer:

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care does not undertake any responsibility to update the forward-looking statements in this release.

Page 2/ 2